Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

MT-802 is a proteolysis-targeting chimera (PROTAC) composed of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Item No. 16274) linked to the cereblon inhibitor pomalidomide (Item No. 19877).1 It induces degradation of BTK in NAMALWA cells when used at concentrations ranging from 10 to 250 nM. MT-802 (1 µM) induces BTK degradation in primary X-linked agammaglobulinemia (XLA) cells expressing wild-type BTK or the ibrutinib-resistant mutant BTKC481S. It also induces BTK degradation in patient-derived chronic lymphocytic leukemia (CLL) cells.
WARNING This product is not for human or veterinary use.
1. Targeting the C481S ibrutinib-